IACS’s novel compound treats drug-resistant kala-azar infection

A team of researchers from the Indian Institute of Chemical Biology (IICB) and the Indian Association for the Cultivation of Science (IACS) have developed a novel compound that could potentially treat drug-resistant kala-azar infection.

Kala-azar, also known as visceral leishmaniasis, is a deadly parasitic disease caused by the Leishmania parasite. It is transmitted to humans through the bite of an infected sandfly and is endemic in many parts of the world, including India. The disease is characterized by fever, weight loss, anemia, and enlargement of the spleen and liver.

The novel compound developed by the IACS and IICB team is a small molecule that targets the Leishmania parasite and has been found to be effective in treating drug-resistant kala-azar infection in laboratory studies. The compound works by inhibiting the activity of an enzyme called cysteine protease, which is essential for the survival of the parasite.

The compound has been tested in animal models and has been found to be safe and effective in treating drug-resistant kala-azar infection. The researchers are now working on optimizing the compound for clinical use.

The development of this novel compound is a major breakthrough in the fight against kala-azar. It could potentially provide a much-needed treatment option for patients with drug-resistant kala-azar infection, who currently have limited treatment options.

The researchers are hopeful that the compound could be developed into a safe and effective drug for the treatment of kala-azar in the near future.